# Immune Effects Shikonin's immune story is smaller than its PKM2 story. It is still worth attention because the mechanisms are specific rather than generic. ### Immunogenic cell death Shikonin can induce immunogenic cell death in breast-cancer models. That matters because immunogenic cell death is not silent. It releases danger signals and tumour antigens that can activate dendritic cells and support tumour-specific T-cell priming. This is the basis for the dendritic-cell-vaccine work built around shikonin-treated tumour cells. That work is early. It still shows a real pathway, not just a theory. ### Tumour-associated macrophage modulation In ovarian-cancer models, shikonin reduces tumour-derived exosome production and limits exosomal GAL3-driven β-catenin activation. The downstream effect is reduced M2-polarised macrophage support inside the tumour microenvironment. That is important because M2 macrophages help tumours suppress immune surveillance and support invasion. ### Necroptosis and inflammatory signalling Necroptosis is inherently more inflammatory than classical apoptosis. When shikonin pushes tumour cells into RIPK1/RIPK3-linked necroptosis, intracellular contents are released in a way that can amplify immune recognition. That may be helpful in immune-cold tumours. It may also raise off-target inflammatory questions. The balance has not been resolved in humans. ### Important limits Several gaps still matter: * no immune-competent human data * no meaningful checkpoint-inhibitor combination literature * most immunogenic-cell-death work comes from breast-cancer models * microenvironment effects remain underexplored in intact animal immune systems ### Bottom line Shikonin has real immune relevance. It is early, mechanistic, and still preclinical. The strongest current angles are immunogenic cell death and macrophage-polarisation effects rather than broad immune enhancement claims. ### Key references Ahmad F et al. (2024). Shikonin in breast cancer treatment — ICD and immune findings. *Journal of Pharmacy and Pharmacology.*\ Frontiers in Pharmacology (2025). Shikonin in female reproductive cancers — macrophage/exosome biology.\ Li Z et al. (2018). Necroptosis and RIPK1-RIPK3 axis — immunogenic cell death context. *PMC.*\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/immune-effects.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.